Myrobalan Therapeutics

Sanofi's Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps
CompanyDrug

Sanofi’s Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Sanofi (NASDAQ: SNY) announced that China's National Medical Products Administration (NMPA) has approved a new indication application for dupilumab (trade name: Dupixent), for use in combination with intranasal corticosteroids in…

Bayer's Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Bayer’s Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support